TerminatedPhase 3

Treatment Chronic UTI Post Kidney Transplant

Stopped: drug not provided

Iran5 participantsStarted 2023-07-01

Plain-language summary

Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E within the first year posttransplant. Moreover, recurrence rates of UTI caused by ESBL-E are almost three times higher than those by cephalosporin-susceptible Enterobacteriums demonstrating the decreased efficacy of antibiotics in the treatment of these UTIs.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Stable Kidney Transplant Recipients * Stable Immunosupression Dose * Stable Renal Function * Resistant Urinary Infection with Positive UC Exclusion Criteria: * Rejection periods * Frail Patients

What they're measuring

Urine culture

Timeframe: 1 week after administration

Trial details

NCT IDNCT05967130

SponsorShahid Beheshti University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-01

View on ClinicalTrials.gov More Urinary Tract Infections trials